The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage
- PMID: 32974367
- PMCID: PMC7466745
- DOI: 10.3389/fmed.2020.00457
The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage
Abstract
National regulatory authorities (NRAs) are the gatekeepers of the supply chain of medical products, and they have a mandate to ensure the quality, safety and efficacy of medicines, vaccines, blood, and blood products, medical devices, including diagnostics and traditional, or herbal medicines. However, the majority of the world's regulators are still struggling to reach a level of maturity, whereby they have a stable, well-functioning and integrated regulatory system. The World Health Organization (WHO) has developed a Global Benchmarking Tool (GBT) as part of its five-step capacity building program to assist NRAs, using the tool, they can benchmark their own strengths and areas of weakness, and then engage in a formal benchmarking process together with WHO and international experts in order to formulate an effective and workable institutional development plan. The GBT is comprehensive across the entire product life cycle and allows benchmarking to be customized to the needs of the NRA. It has evolved from decades of experience using a variety of benchmarking tools, within WHO and other stakeholder organizations. By the end of December 2019, 26 countries had undergone formal benchmarking, and a further 54 countries had used the GBT to conduct self-benchmarking exercises assisted by WHO.
Keywords: GBT; NRA; RSS; global benchmarking tool; national regulatory authority; regulation; regulation of medical products; regulatory systems strengthening.
Copyright © 2020 Khadem Broojerdi, Baran Sillo, Ostad Ali Dehaghi, Ward, Refaat and Parry.
Figures




Similar articles
-
The WHO Global Benchmarking Tool: a game changer for strengthening national regulatory capacity.BMJ Glob Health. 2020 Aug;5(8):e003181. doi: 10.1136/bmjgh-2020-003181. BMJ Glob Health. 2020. PMID: 32784212 Free PMC article. Review.
-
Leveraging WHO's Global Benchmarking Tool to strengthen capacity in clinical trials oversight for public health emergencies: the GHPP VaccTrain model.Global Health. 2022 Jun 20;18(1):63. doi: 10.1186/s12992-022-00854-0. Global Health. 2022. PMID: 35725614 Free PMC article.
-
The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the World Health Organization Global Benchmarking Tool standards.Cytotherapy. 2024 Aug;26(8):954-966. doi: 10.1016/j.jcyt.2024.04.070. Epub 2024 Apr 27. Cytotherapy. 2024. PMID: 38739075 Review.
-
Identifying and costing common gaps in Central and West Africa pharmaceutical regulation.Front Med (Lausanne). 2024 Apr 5;11:1362253. doi: 10.3389/fmed.2024.1362253. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38660423 Free PMC article.
-
The capacity of young national medicine regulatory authorities to ensure the quality of medicines: case of Rwanda.J Pharm Policy Pract. 2022 Nov 24;15(1):90. doi: 10.1186/s40545-022-00492-2. J Pharm Policy Pract. 2022. PMID: 36434730 Free PMC article.
Cited by
-
Implementation and performance of haemovigilance systems in 10 sub-saharan African countries is sub-optimal.BMC Health Serv Res. 2021 Nov 20;21(1):1258. doi: 10.1186/s12913-021-07235-0. BMC Health Serv Res. 2021. PMID: 34801022 Free PMC article.
-
Burden of and factors associated with poor quality antibiotic, antimalarial, antihypertensive and antidiabetic medicines in Malawi.PLoS One. 2022 Dec 27;17(12):e0279637. doi: 10.1371/journal.pone.0279637. eCollection 2022. PLoS One. 2022. PMID: 36574444 Free PMC article.
-
Economic assessment of potential changes to essential medicines for diabetes in Uganda.PLoS One. 2025 Jun 25;20(6):e0326806. doi: 10.1371/journal.pone.0326806. eCollection 2025. PLoS One. 2025. PMID: 40560893 Free PMC article.
-
How the concept of WHO-listed authorities will change international procurement policies for medicines.BMJ Glob Health. 2022 Feb;6(Suppl 3):e008109. doi: 10.1136/bmjgh-2021-008109. BMJ Glob Health. 2022. PMID: 35144982 Free PMC article. No abstract available.
-
WHO-listed authorities (WLA) framework: transparent evidence-based approach for promoting regulatory reliance towards increased access to quality-assured medical products.Front Med (Lausanne). 2024 Sep 23;11:1467229. doi: 10.3389/fmed.2024.1467229. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39376648 Free PMC article.
References
-
- Sixty-seventh World Health Assembly WHA 67.20: Regulatory Systems Strengthening for Medical Products. Geneva: World Health Organization; (2014).
-
- Regulatory system strengthening World Health Organization. Available online at: https://www.who.int/medicines/regulation/rss/en/ (accessed October 4, 2019).
-
- World Health Organization Essential Medicines and Health Products. Assessing National Medicines Regulatory Systems. Available online at: https://www.who.int/medicines/areas/quality_safety/regulation_legislatio... (accessed July 19, 2019).
-
- Good Regulatory Practices: Guidelines for National Regulatory Authorities for Medical Products Geneva: World Health Organization; (2016). Available online at: https://www.who.int/medicines/areas/quality_safety/quality_assurance/Goo... (accessed October 22, 2019).
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous